Diabetic Peripheral Neuropathy - Pipeline Insight 2018 - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--Dec 21, 2018--The “Diabetic Peripheral Neuropathy - Pipeline Insight, 2018” drug pipelines has been added to ResearchAndMarkets.com’s offering.
‘Diabetic Peripheral Neuropathy - Pipeline Insight, 2018’ report offers comprehensive Insight of the pipeline (under development) therapeutics scenario and growth prospects across Diabetic Peripheral Neuropathy development. The report provides detailed coverage of the pipeline landscape for this mechanism of action, equipped with data from multiple sources with complete pipeline analysis by developmental stage, associated indications, route of administration and molecule type.
Pipeline Products covered across the following Developmental Stages:Clinical Non-clinical Inactive: Discontinued and/or Dormant
Pipeline therapeutics development coverage provides descriptive product profiles including (but not limited to) drug description, product development and R&D activities encompassing clinical and pre-clinical studies, designations, collaborations, licensing deals, grants, technologies and patent details.
The report assesses the active Diabetic Peripheral Neuropathy pipeline products by developmental stage, product type, molecule type, and administration route.
Key Topics Covered:
1. Report Introduction
2. Diabetic Peripheral Neuropathy Overview
3. Pipeline Therapeutics
4. Comparative Analysis
5. Products in Clinical Stage
6. Products in Pre-Clinical and Discovery Stage
7. Therapeutic AssessmentAssessment by Route of Administration Assessment by Stage and Route of Administration Assessment by Molecule Type Assessment by Stage and Molecule Type
8. Inactive Products
Companies MentionedAchelios Therapeutics Inc Celgene Corp Commence Bio Inc KPI Therapeutics Inc Medifron DBT Co Ltd Relief Therapeutics Holding AG ViroMed Co Ltd
For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/lwsgvh/diabetic?w=4
View source version on businesswire.com:https://www.businesswire.com/news/home/20181221005329/en/
Laura Wood, Senior Press Manager
For E.S.T. Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics:Central Nervous System Drugs,Endocrine and Metabolic Disorders Drugs
INDUSTRY KEYWORD: HEALTH PHARMACEUTICAL
SOURCE: Research and Markets
Copyright Business Wire 2018.
PUB: 12/21/2018 10:29 AM/DISC: 12/21/2018 10:28 AM